Immunity for pneumococal vaccine. Pneumonia due to Streptococcus pneumoniae
Conditions
Interventions
Intervention 1: pneumococcal vaccine 23 valent (Merck Company, Germany) injected into the deltoid muscle, intramuscularly, as well as Zinc sulfate capsules (Alhavy company, Iran) 200 mg daily, PO for
Prevention
pneumococcal vaccine 23 valent (Merck Company, Germany) injected into the deltoid muscle, intramuscularly, as well as Zinc sulfate capsules (Alhavy company, Iran) 200 mg daily, PO for a month
pneumococcal vaccine 23 valent (Merck Company, Germany) injected into the deltoid muscle, intramuscularly, as well as placebo (capsules filled with sugar) for a month
Sponsors
Kermanshah University Medical Sciences
Eligibility
Sex/Gender
All
Age
65 Years to 120 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age 65 years of age, no lung infection, full consent to participate in the study, no allergic or any other systemic diseases, Pneumococcal vaccination the past three years
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunity against pneumococcal vaccine. Timepoint: One Month. Method of measurement: ELIZA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Edema and Indurations due to vaccine. Timepoint: One Month. Method of measurement: Observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSayed Mohamad Karimi Vafa
Kermanshah University of Medical Sciences
Outcome results
None listed